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Since 2004, the clinical impact of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) on patients
with metastatic colorectal cancer (MCRC) has been clearly established. The combination of these biological agents with conventional
chemotherapy has led to a significant improvement in response rate, progression-free survival and overall survival in first-line as well as
in second- or third-line treatment of MCRC. However, the high variability of response and outcome in MCRC patients treated with
these anti-EGFR mAbs has highlighted the need of identifying clinical and/or molecular predictive markers to ensure appropriate use
of targeted therapies. The presence of somatic KRAS mutations has been clearly identified as a predictive marker of resistance to
anti-EGFR in MCRC, and the use of anti-EGFR mAbs is now restricted to patients with no detectable KRAS mutation. Several studies
have indicated that amplification of EGFR, overexpression of the EGFR ligands and inactivation of the anti-oncogene TP53 are
associated with sensitivity to anti-EGFR mAbs, whereas mutations of BRAF and PIK3CA and loss of PTEN expression are associated
with resistance. Besides these somatic variations, germline polymorphisms such as those affecting genes involved in the EGFR pathway
or within the immunoglobulin receptors may also modulate response to anti-EGFR mAbs. Until now, all these markers are not
completely validated and only KRAS genotyping is mandatory in routine practice for use of the anti-EGFR mAbs in MCRC.
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Colorectal cancer (CRC) is the third most common cancer
worldwide. Synchronous metastases are estimated to occur in
25% of patients, and B40–50% of patients with newly diagnosed
CRC develop secondary metastases (Meyerhardt and Mayer, 2005).
Since 2004, numerous studies have demonstrated the efficiency of
monoclonal antibodies (mAbs) targeting the epidermal growth
factor receptor (EGFR) ectodomain, such as cetuximab and
panitumumab, in patients with metastatic colorectal cancer
(MCRC). Cetuximab corresponds to a chimeric mouse human
IgG1 mAb, and panitumumab is a fully human IgG2 mAb.
Indeed, several randomised trials conducted in chemorefractory
as well as in chemonaive MCRC patients have reported significant
results for cetuximab and panitumumab monotherapy or chemo-
therapy-based (CT) regimens (Cunningham et al, 2004; Jonker
et al, 2007; Van Cutsem et al, 2007, 2009a; Bokemeyer et al, 2009).
In a randomised phase II trial including irinotecan-refractory
MCRC patients, Cunningham et al (2004) reported that cetuximab
plus irinotecan significantly improved the response rate and
progression-free survival (PFS) when compared with cetuximab
alone (22.9 vs 10.8% and 4.1 vs 1.5 months, respectively). Recently,
a phase III randomised trial conducted by Van Cutsem et al
(2009a,b) showed that in chemonaive MCRC patients, the addition
of anti-EGFR to irinotecan-based CT lead to an 8.2% increase in
the objective response (46.8 vs 38.4%), a 0.9-month increase in the
PFS (8.9 vs 8 months) and a 1.3-month increase in the overall
survival (OS) (19.9 vs 18.6 months). Although the response to
anti-EGFR mAbs observed in some patients has confirmed that
EGFR activation is oncogenic, as predicted by cellular and animal
models, the molecular mechanisms underlying EGFR activation in
colorectal cancer remain obscure and are probably heterogeneous.
This situation contrasts with in lung adenocarcinoma in which the
key mechanism of EGFR activation underlying sensitivity to EGFR
inhibitors corresponds to activating mutations within the EGFR
tyrosine kinase domain. Although the use of anti-EGFR mAbs was
initially restricted to MCRC patients with a detectable expression
of EGFR by immunochemistry (IHC), the lack of IHC predictive
value and the heterogeneous clinical response have highlighted the
need to identify reliable markers predictive of response to anti-
EGFR mAbs (Chung et al, 2005).
Two types of molecular predictive markers have been investi-
gated. The majority of studies published so far have analysed
somatic alterations affecting effectors of EGFR pathways, such as
the receptor–ligand complex, the RAS–RAF–mitogen-activated
protein kinase (MAPK) and phosphatidylinositol 3 kinase
(PI3K)–Akt–PTEN transduction cascades and p53 (Moroni
et al, 2005; Lie `vre et al, 2006, 2008; Benvenuti et al, 2007; Di Fiore
et al, 2007; Frattini et al, 2007; Khambata-Ford et al, 2007; Amado
et al, 2008; De Roock et al, 2008; Di Nicolantonio et al, 2008;
Oden-Gangloff et al, 2009; Van Cutsem et al, 2009a). Studies have
indicated that amplification of EGFR and overexpression of the
EGFR ligands are associated to sensitivity to anti-EGFR mAbs,
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expression are associated with resistance (Figure 1, bottom panel).
The second type of predictive markers investigated are germline
polymorphisms of genes involved in the EGFR pathway (Khamba-
ta-Ford et al, 2007; Graziano et al, 2008; Garm Spindler et al, 2009)
or within the immunoglobulin receptors, considering the potential
role of antibody-dependent cellular cytotoxicity (ADCC) in the
action of anti-EGFR mAbs (Zhang et al, 2007; Bibeau et al, 2009).
At the present time, the only molecular marker predictive of the
response to anti-EGFR mAbs, which has been unambiguously
validated in MCRC by numerous studies, is the somatic mutation
of KRAS as a marker of resistance to anti-EGFR (Lie `vre et al, 2006,
2008; Di Fiore et al, 2007; Frattini et al, 2007; Amado et al, 2008; De
Roock et al, 2008; Van Cutsem et al, 2009a). This has led to
systematic KRAS genotyping in MCRC patients and to the
restriction of anti-EGFR mAbs to patients with no detectable
KRAS mutation. Nevertheless, KRAS mutations are obviously not
the only determinants of the clinical response to anti-EGFR.
OVERVIEW OF THE EGFR PATHWAY
The receptors of EGF are composed of homodimers or hetero-
dimers of four related glycoproteins: HER1 (or EGFR), HER2
(or Erbb2), HER3 and HER4 (Figure 1, top panel). These receptors
are composed of an extracellular ligand-binding domain, a
transmembrane segment and an intracellular protein tyrosine
kinase domain. In a normal cell, activation of EGFR is induced by
the binding of the ligands to the ectodomain (Ciardiello and
Tortora, 2001, 2008). Approximately ten ligands can activate the
EGFR pathway. The ligands for HER1/EGFR are EGF, TGF-a,
HB-EGF, amphiregulin, epiregulin and VGF; heregulins are the
ligands of Her-3; NRG2, NRG3, heregulins and b-cellulin are the
ligands of ErbB-4, and Her-2 is an orphan receptor. Binding of the
ligands will induce EGFR homodimerisation (EGFR-EGFR) or
heterodimerisation (EGFR-HER2; EGFR-HER3 or EGFR-HER4)
and then ATP-dependent phosphorylation of tyrosine residues
located within the intracellular domain. The phosphorylated EGFR
will then lead to the activation of the RAS–RAF–MAPK kinase
and the PI3K–Akt transduction cascades. The RAS–RAF–MAPK
kinase is the major downstream signalling route of the EGFR
pathway and it controls cell-cycle progression, differentiation,
survival and in particular, the G1/S-phase transition (Ciardiello
and Tortora, 2008). The RAS proteins are members of a large
superfamily of guanine guanosine-50-triphosphate (GTP) and
guanine guanosine-50-diphosphate (GDP)-binding proteins. In
normal cells, EGFR activates RAS by stimulating its binding to
GTP. RAF will then be activated and will phosphorylate the
MAP2K1 and MAP2K2 kinases. The p110 subunit of PI3K encoded
by the PIK3CA oncogene is activated by RAS proteins. The PI3K–
Akt pathway, which is negatively regulated by the PTEN protein,
activates antiapoptotic and survival signals (Figure 1, top panel).
In cancerous cells, EGFR pathway activation results in cell
proliferation, inhibition of apoptosis, activation of invasion,
metastasis and tumour neovascularisation (Ciardiello and Tortora,
2001, 2008; Cohen et al, 2005). The main mechanism of EGFR
activation, so far characterised in CRC, corresponds to the somatic
mutation of the KRAS proto-oncogene. Somatic mutations of
KRAS are detected in B30–40% of CRCs (Andreyev et al, 2001).
These activating mutations are missense mutations that intro-
duce amino-acid substitutions mainly at positions 12, 13 and 61.
Activating mutations of other EGFR pathway effectors have also
been described. In CRC, mutations of BRAF and PI3K genes are
detected in B5–10% and 6–13% of the tumours, respectively
(Moroni et al, 2005; Lie `vre et al, 2006; Di Nicolantonio et al, 2008;
Laurent-Puig et al, 2009; Prenen et al, 2009; Sartore-Bianchi et al,
2009). Somatic mutations of KRAS and BRAF are mutually exclusive.
KRAS MUTATION: A VALIDATED PREDICTIVE
MARKER OF RESISTANCE TO ANTI-EGFR
Since 2004, the predictive value of somatic KRAS mutation, in
terms of resistance to anti-EGFR mAbs, has been established by
numerous studies. These studies (see Table 1), mainly focusing on
mutations of codons 12 and 13, and more recently on codon 61,
have been based on molecular analyses of tumour-extracted DNAs
from patients included in retrospective studies, as well as in
prospective randomised trials (Lie `vre et al, 2006, 2008; Benvenuti
et al, 2007; Di Fiore et al, 2007; Frattini et al, 2007; Amado et al,
2008; De Roock et al, 2008; Bokemeyer et al, 2009; Loupakis et al,
2009a; Van Cutsem et al, 2009a). The first line of evidence that
KRAS mutation was a strong predictor of resistance to anti-EGFR
mAbs was the observation that in chemorefractory patients treated
with cetuximab-based CT, o2% of patients with detectable KRAS
mutation exhibited an objective response, whereas B40% of
patients with no detectable KRAS mutation showed a clinical
response (Lie `vre et al, 2006, 2008; Benvenuti et al, 2007; Di Fiore
et al, 2007, 2008a,b; Frattini et al, 2007; De Roock et al, 2008;
Loupakis et al, 2009a). The impact of KRAS status in response to
anti-EGFR mAbs was also documented by trials in chemorefrac-
tory patients comparing cetuximab or panitumumab monotherapy
vs best supportive care, with an increase in the response rate in
patients with no KRAS mutation from 8 to 12.8% and from 10 to
17%, respectively (Karapetis et al, 2008).
In chemonaive patients with no detectable KRAS mutation, the
addition of anti-EGFR antibodies to CT increased the objective
response from approximately 46 to 60% when compared with CT
KRAS
PI3K
PTEN AKT
BRAF
MEK/ERK
Proliferation
Angiogenesis migration survival
Ligands
EGFR
KRAS
PI3K
PTEN AKT
BRAF
MEK/ERK
Proliferation
Angiogenesis migration survival
KRAS
PI3K
PTEN AKT
BRAF
MEK/ERK
Proliferation
Angiogenesis migration survival
Anti-EGFR 
mAb
Sensitivity Resistance
Figure 1 An overview of the EGFR pathway and its main downstream
effectors (top). Expected outcomes of anti-EGFR (mAb) therapy (bottom):
sensitivity (tumour response) when EGFR is activated (gain copy number,
ligand overexpression, other unknown mechanisms) and downstream
effectors are wild type (left); resistance (tumour development and
metastasis) when downstream effectors such as KRAS, BRAF or PI3K are
activated or PTEN is inactivated (right).
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Van cutsem et al, 2009a). Except in the recent COIN randomised
trial (Maughan et al, 2009), the addition of anti-EGFR mAbs to CT
has also been shown to lead to a significant increase in the median
PFS when compared with irinotecan- or oxaliplatin-based CT
alone in chemonaive as well as in chemorefractory patients. In
contrast, in mutant KRAS patients, no clinical benefit was observed
from the combination of anti-EGFR plus CT. The effect of KRAS
status on OS in MCRC patients treated in first line remains
debatable, with contradictory results that are mainly explained by
the non-standardisation of second- and third-line CT as well as
several confounding factors such as treatment crossover and
different monitoring methods used in these such randomised trials
(Douillard et al, 2009; Van Cutsem et al, 2009a,b).
OTHER SOMATIC PREDICTIVE MARKERS OF
RESPONSE TO ANTI-EGFR
PIK3CA and PTEN alterations
The demonstration that in MCRC patients KRAS mutations confer
resistance to anti-EGFR has validated the hypothesis that targeting
EGFR will be inefficient if activation of the EGFR transduction
cascade results from somatic alterations affecting downstream
effectors (Figure 1, bottom panel). This led to an investigation of
the predictive value of somatic alterations affecting other effectors.
In colorectal cancer, activation of the PIK3CA pathway can result
either from activating PIK3CA mutations or from inactivation of
the PTEN protein. Since 2005, the impact of PIK3CA mutations on
MCRC patients treated with anti-EGFR has been investigated by
several studies that have reported a PIK3CA mutation frequency
ranging from 6 to 13% (Moroni et al, 2005; Lie `vre et al, 2006;
Perrone et al, 2009; Prenen et al, 2009; Sartore-Bianchi et al, 2009).
In the studies of Moroni et al (2005), Lie `vre et al (2006) and
Perrone et al (2009), none of the responders to anti-EGFR therapy
had a PIK3CA mutation, but this association was not statistically
significant, given the limited number of patients. In contrast, a
significant association between the presence of PIK3CA mutation
and response to anti-EGFR has been recently reported by Sartore-
Bianchi et al (2009) in a study including 110 patients treated with
anti-EGFR mAbs. A total of 32 (29%) patients had a KRAS
mutation and 15 (13%) had a PIK3CA mutation. When compared
with the unselected population, the response rate to anti-EGFR
increased from 20 to 26% in patients with no KRAS mutation, to
23% in patients with no PIK3CA mutation and to 31% in patients
with no KRAS/PIK3CA mutations (Sartore-Bianchi et al, 2009).
Nevertheless, these results were not confirmed by the recent study
of Prenen et al (2009), in which PIK3CA mutations were identified
in 5 of 39 (13%) responders vs 18 of 160 (11%) nonresponders
(P¼0.781). These contradictory results highlight the fact that the
association between PIK3CA mutations and resistance to anti-
EGFR is not yet validated.
PTEN exerts an effect as a tumour suppressor by dephos-
phorylating the plasma membrane lipid second messenger PIP-3
generated by the action of PI3KCA. The loss of PTEN function
induces an increase in PIP-3 concentration and PIK3CA pathway
activation. IHC and FISH analyses are the two main methods that
have been used to evaluate the PTEN status in studies focused on
anti-EGFR resistance. However, the molecular mechanisms leading
to PTEN inactivation are heterogeneous and include genomic
deletions, inactivating mutations and promoter hypermethylation,
indicating that PTEN integrity cannot be explored by a simple
method. In a series of 27 MCRC patients, Frattini et al (2007)
reported that PTEN alteration detected by IHC in primary tumours
was significantly associated with cetuximab resistance. More
recently, Loupakis et al (2009b) have analysed by IHC the impact
of PTEN cytoplasmic staining intensity in 85 primary tumours and
55 related metastases from patients treated with cetuximab plus
irinotecan. First, using a specific scoring system for PTEN
expression, these authors found that IHC staining was concordant
in only 27 out of 45 (60%) pairs of assessable primary and related
metastases. Second, the results of the PTEN IHC performed on the
85 primary tumours did not correlate with the response and PFS,
whereas PTEN IHC analysis performed on the 55 metastases was
significantly associated with response rate and PFS. When the
KRAS mutational status in the primary tumours and the PTEN
expression in metastasis were combined, the subgroup of patients
with no detectable KRAS mutation and positive to PTEN had a
significantly higher response and longer PFS than patients with
KRAS mutation and negative to PTEN. In patients with no KRAS
mutation, Laurent-Puig et al (2009) found that the absence of
PTEN expression, detected in 19.9% of patients using another IHC
scoring system, was associated with shorter OS in univariate
and multivariate analyses. In a series of 72 MCRC patients treated
with anti-EGFR mAbs plus CT, Razis et al (2008) evaluated the
Table 1 Response rate (OR) and PFS in MCRC patients treated with anti-EGFR mAb-based CT
Regimen(s) Study n
Response
KRAS WT (%) P-value
PFS KRAS
WT (months) P-value
Chemonaive patients: 1st line
Cmab+FOLFOX vs FOLFOX Bokemeyer et al (2009, 2010) 315 57.3 vs 34.0 0.0027 8.3 vs 7.2 0.0064
Cmab+FOLFIRI vs FOLFIRI Van Cutsem et al (2009a,b, 2010) 1063 57.3 vs 39.7 o0.0001 9.9 vs 8.4 o0.0012
Pmab+FOLFOX vs FOLFOX Douillard et al (2009) 1183 55.0 vs 48.0 NS 9.6 vs 8.0 0.02
Chemorefractory patients: 2nd line
Pmab + FOLFIRI vs FOLFIRI Peeters et al (2009) 1186 35 vs 10 o0.01 5.9 vs 3.9 0.004
Chemorefractory patients: X2nd line
Cmab±CT Lie `vre et al (2006) 30 40.7 — — —
Cmab±CT Di Fiore et al (2007) 59 27.9 — 5.5 —
Cmab±CT Lie `vre et al (2008) 114 43.5 — 7.4 —
Cmab±CT De Roock et al (2008) 80 45.8 — 7.9 —
Cmab/Pmab±CT Benvenuti et al (2007) 48 31.2 — — —
Chemorefractory patients: 43rd line
Cmab mono vs BSC Karapetis et al (2008) 394 12.8 vs 0 — 3.7 vs 1.9 o0.001
Pmab mono vs BSC Amado et al (2008) 427 17 vs 0 — 2.9 vs 1.7 o0.0001
Abbreviations: BSC¼best supportive care; CI¼confidence interval; Cmab¼cetuximab; CT¼chemotherapy; EGFR¼epidermal growth factor receptor; mAb¼monoclonal
antibody; MCRC¼metastatic colorectal cancer; NS¼not significant; OS¼overall survival; PFS¼progression-free survival; Pmab¼panitumumab; WT¼wild type.
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The absence of PTEN gene dosage alteration was significantly
associated with response rate, whereas PTEN gene deletion was
correlated with worse PFS. No significant association was found
using PTEN IHC expression. All these results clearly indicate that
no obvious association has yet been established between PTEN
alterations and anti-EGFR therapy in MCRC patients. It should
also be noted that commercially available anti-PTEN antibodies do
not always provide reproducible results in IHC. Further studies are
needed to determine the most efficient and reproducible methods for
PI3KCA and PTEN analysis in order to clearly evaluate the predictive
value of each marker separately or in combination with KRAS status.
BRAF mutation
Two studies support that V600E mutation, resulting in strong
activation of the BRAF protein downstream to KRAS, was
associated with shorter PFS and OS in MCRC chemorefractory
patients treated with anti-EGFR mAbs (Di Nicolantonio et al, 2008;
Laurent-Puig et al, 2009). Nevertheless, it seems that whatever the
treatment, this mutation in MCRC is mainly associated with poor
prognosis, which may interfere with its predictive value regardless
of anti-EGFR mAbs (Tol et al, 2010; Van Cutsem et al, 2010).
TP53 mutations
In a normal cell, the p53 protein exerts an effect not only as a
guardian of the genome, which is activated when DNA damage
occurs, but also as a policeman of oncogenes, which become active
when oncogenes are inappropriately activated, thus inducing
apoptosis and/or senescence (Efeyan and Serrano, 2007; Halazo-
netis et al, 2008). Alteration of the p53 pathway has been reported
to be systematically observed in non-small cell lung cancer with
activating EGFR mutations, suggesting that p53 inactivation is
required to allow expansion of a cell with EGFR pathway activation
(Mounawar et al, 2007). On the other hand, it has been shown that
PI3K signalling activates p53-mediated growth suppression,
suggesting that p53 exerts an effect as a brake for the activated
PI3K transduction cascade (Kim et al, 2007). Taken together, these
data led us to formulate the hypothesis that activation of the EGFR
pathway should be oncogenic, and therefore anti-EGFR antibodies
should only be efficient in tumours, only if p53 is inactivated.
We have recently analysed the impact of TP53 mutations on 64
MCRC patients treated with cetuximab plus CT (Oden-Gangloff
et al, 2009). In this series, TP53 mutations were found in 41 of 64
patients and were significantly associated with controlled disease
(P¼0.037) and higher PFS (20 vs 12 weeks, P¼0.004). In the
subgroup of patients without KRAS detectable mutation, we have
also found that controlled disease and PFS were significantly
improved in TP53 mutated patients when compared with TP53
nonmutated patients. These results might be explained not only by
the fact that EGFR activation is oncogenic only if TP53 is
inactivated, but also by the fact that inactivation of TP53 could
be one of the mechanisms leading to EGFR activation. Cellular
models and studies on larger MCRC series are necessary to clarify
the relationship between TP53 status and sensitivity to anti-EGFR.
EGFR gene copy number and expression of its ligands
EGFR gene copy number A common mechanism of EGFR
activation is the increase in the EGFR copy number corresponding
to the gain of copies or amplification of the chromosome 7 region
on which EGFR is located. A copy number increase of EGFR
resulting from chromosome 7 polysomy probably does not have
the same biological significance than amplification of the EGFR
locus. In contrast to breast cancer in which tumour cells exhibit
HER2 amplification in homogeneous regions with a relationship
between expression and gene amplification, colorectal cancer is
characterised by a heterogeneous EGFR gene copy number pattern
and, furthermore, no correlation has been established between the
EGFR copy number and the EGFR IHC staining. Based on the
results obtained in patients with metastatic breast cancer treated
with trastuzumab, in which ERBB2 amplification correlates with
sensitivity to mAb therapy, Moroni et al (2005) investigated the
impact of the EGFR gene copy number, assessed by FISH, on the
anti-EGFR mAb response in a series of 30 MCRC patients. This
study reported a positive significant association between an
increased EGFR gene copy number and the response rate to
cetuximab or panitumumab. Since 2005, many reports have
investigated the relationship between EGFR copy number and
response to mAb therapy in MCRC, but only five of them restricted
the analysis to the subgroup of wild-type KRAS patients (Table 2).
Although an increase in EGFR copy number is significantly
associated with mAb therapy response, the results are less obvious
in terms of PFS or OS. Cappuzzo et al (2008), in a series of 85
chemorefractory patients treated with cetuximab, determined that
the best cutoff significantly associated with the response rate and
PFS was 2.92 EGFR gene copy number per cell. Interestingly, these
authors further analysed their population according to the EGFR
copy number cutoff previously reported by Sartore-Bianchi et al
(2009) and observed a significant association for response rate but
not for PFS. It can be concluded from the different studies
Table 2 Influence of EGFR status (gene copy number) on subject response in KRAS wild-type MCRC patients treated with anti-EGFR mAb-based CT
PFS (months) OS (months)
Responders Nonresponders
Study N EGFR cutoff No 95% CI P-value No 95% CI P-value CR+PR SD+PD P-value
Moroni et al (2005) 20 X3
a — — 6 1 0.001
o3— — 1 1 2
Personeni et al (2008) 58 X2.83
a 5.5 0.25 10 0.037 17 10 0.007
o2.83 4 8.3 8 23
Laurent-Puig et al (2009) 116 X2
a 8.5 7–16 0.28 20 13–NA 0.018 12 5 0.015
o2 7 5–8.5 14 11–17 29 50
Scartozzi et al (2009) 44 X2.6
a 7.7 0.04 16 0.2 9 6 0.001
o2.6 2.9 9.5 2 21
X2.12
b 6.4 0.02 10.6 0.95 10 18 0.04
o2.12 3.1 10.3 1 15
Tol et al (2010) 155 X3
a 9.5 6.4–12.3 0.19 21.9 13.4–27.1 0.65 — —
o3 10.4 8.6–12.2 22 19.2–25.4 — —
Abbreviations: CI¼confidence interval; CISH¼chromogenic in situ hybridisation; CR¼complete response; CT¼chemotherapy; EGFR¼epidermal growth factor receptor;
FISH¼fluorescence in situ hybridisation; mAb¼monoclonal antibody; MCRC¼metastatic colorectal cancer; NA¼not assessable; OS¼overall survival; PFS¼progression-free
survival; PR¼partial response; PD¼progressive disease; SD¼stable disease.
aFISH.
bCISH.
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resulting from gene amplification and observed in a small fraction
of patients, is probably predictive of anti-EGFR sensitivity in
MCRC patients.
Expression of EGFR ligands Few studies have investigated the
predictive role of EGFR ligand expression on anti-EGFR response
in MCRC. A transcriptome analysis of 164 CRCs, using a 640 probe
set, showed that the EGFR ligands, epiregulin (EREG) and
amphiregulin (AREG), were highly expressed in 25% of the
samples (Khambata-Ford et al, 2007). In this study, analysis of
metastatic frozen samples from a population of 80 MCRC patients
treated with cetuximab monotherapy showed that patients with
disease control expressed the EGFR ligands at a higher level than
nonresponders. Moreover, patients with tumours exhibiting higher
EREG or AREG expression had significantly longer PFS, suggesting
that these tumours were EGFR dependent and were therefore
particularly sensitive to the inhibition of the ligand–receptor
interaction by anti-EGFR mAb (Khambata-Ford et al, 2007).
In a recent study performed on paraffin-embedded samples in
refractory MCRC patients treated with cetuximab and irinotecan,
the KRAS status and the EREG and AREG mRNA expression were
first determined on 220 primary samples and the results were then
validated on a series of 67 patients (Jacobs et al, 2009). The mRNA
levels of EREG and AREG significantly correlated with the absence
of detectable KRAS mutation. When ligand expression level was
combined with the KRAS status, the median OS was 65 weeks in
patients with no detectable KRAS mutation and a high EREG
expression vs 31 weeks (P¼0.01) in patients without detectable
KRAS mutation and low EREG expression (Jacobs et al, 2009).
GERMLINE POLYMORPHISMS ASSOCIATED WITH
CLINICAL RESPONSE TO ANTI-EGFR MABS
Three types of germline polymorphisms suspected of modulating
the response to anti-EGFR have been investigated. The first
corresponds to a CA repeat present within the EGFR intron 1,
which has been shown to modulate EGFR transcription efficiency,
the longer (L) repeats being associated with a reduced transcrip-
tion when compared with the shorter (S) ones. The second, located
within the EGF gene, corresponds to a SNP (G4A, rs4444903). In
110 chemorefractory MCRC patients treated with cetuximab–
irinotecan, Graziano et al (2008) showed that EGFR intron-1
variant (S/S vs L/L and L/S) and EGF61 variant (G/G vs A/A and
A/G) were significantly associated with a better OS. Similar results
were obtained on EGF61 genotypes in a study on chemorefractory
MCRC patients treated with cetuximab plus irinotecan CT (Garm
Spindler et al, 2009). In patients with no detectable KRAS
mutation, homozygous phenotypes (A/A and G/G) were associated
with a lower progression rate (19 vs 60%) than EGF61 A/G patients
(P¼0.006) and a significant increase in OS (17.1 vs 5.9 months).
The third type of germline polymorphism investigated, in the
context of anti-EGFR therapies in MCRC, corresponds to
polymorphic amino-acid substitutions within the receptors of the
Fc fragment of the immunoglobulins (Igs). The H131R and V158F
variations within the Fcg RIIa and Fcg RIIIa have been shown to
modify the affinity of the Ig receptors and are therefore predicted
to modulate the ADCC in patients receiving anti-EGFR IgG1 mAb.
To date, only four studies have found significant association
between these polymorphisms and the clinical outcome. In a first
study performed in a series of 39 chemorefractory patients treated
with cetuximab monotherapy, Zhang et al (2007) found that the
presence of the FCGR2A 131 H allele and of the FCGR3A 158 F
allele were significantly associated with better PFS; however, these
results could not be replicated on a larger series including 130
subjects (Lurje et al, 2008). In 64 chemorefractory MCRC patients
treated with cetuximab-based CT, Bibeau et al (2009) found that
the FCGR2A 131 H/H and FCGR3A 158 V/V genotypes, predicted
to result in a higher affinity of the Ig to the receptor, were
significantly associated with better PFS. In this study, analysis of
these germline polymorphisms in the subgroup of patients with no
detectable KRAS mutation showed that the median PFS was 9.6
months in the 131 H/H or 158 V/V patients vs 4.6 months in the
subgroup of patients harbouring the other genotypes (P¼0.015).
In contrast, a more recent study (Pander et al, 2010), performed on
KRAS wild-type patients receiving chemotherapy plus cetuximab,
showed that subjects homozygous for the FCGR3A 158 F allele
have a better PFS than those bearing other allelic combinations.
Several factors may account for these discrepancies; although
ethnic origin is unlikely to be involved, previous treatment
regimens and association of irinotecan with cetuximab could
modify patients’ response. Further studies involving testing
integrity of the EGFR pathway are clearly needed to clarify this
point.
MUTATIONAL STATUS IN PRIMARY COLORECTAL
ADENOCARCINOMAS AND RELATED METASTASES
One of the main subjects of debate is the relevance of KRAS
genotyping on primary tumours, whereas anti-EGFR mAbs are
used to treat a metastatic disease. Indeed, some publications have
indicated that concordance of mutational status of KRAS and other
EGFR downstream effectors between primary and metastases is not
absolute. In a series of 48 CRC patients, an overall concordance of
92% was observed between primary tumours and metastases for
the presence of mutations within KRAS exon 2 and BRAF exon 5
(Artale et al, 2008); however, in the specific subgroup of patients
with KRAS mutation, 23% of discordance was observed between
the two tumour sites. In a study including 38 MCRCs, Molinari
et al (2009) reported a concordance for KRAS and BRAF
mutational status of 92 and 100%, respectively. More recently,
the analysis of KRAS, BRAF and PIK3CA in tumour invasion
fronts, lymph nodes and distant metastases revealed a discordance
between primary tumours and lymph node metastases of 31, 4 and
13%, respectively (Baldus et al, 2010). A discordance between
primary tumours and distant metastases was observed for KRAS in
10% of the cases and for PIK3CA in 5% of the cases (Baldus et al,
2010). In a large series of 4800 samples tested for KRAS, using a
highly sensitive SNaPshot-based method (Di Fiore et al, 2007), we
observed a discordant KRAS mutational status between tumours
and metastases in 10% of the paired samples (Lamy et al, 2010).
These studies clearly indicate that given the genetic heterogeneity
and genetic evolution of CRC under treatment, the most
appropriate tissue on which molecular profiling should be
performed remains to be determined.
CONCLUSION AND PERSPECTIVES
In conclusion, the numerous studies published since 2006 on the
markers of sensitivity and resistance to anti-EGFR mAbs in MCRC
have clearly validated somatic KRAS mutations as markers of
resistance to anti-EGFR, resulting in restricted use of these
targeted therapies to patients with no detectable KRAS mutation.
However, in these patients, the heterogeneity of response strongly
suggests that several genetic variations, corresponding either to
somatic alterations present only within the tumours or to germline
polymorphisms, can modulate sensitivity or resistance to
anti-EGFR mAbs. One of the challenges is now to identify these
other genetic predictive markers, using either candidate gene
approaches, global analysis based on pangenomic/transcriptomic/
proteomic portraits or cellular or animal models. Some technical
and conceptual questions concerning KRAS genotyping remain
unsolved. One important question under debate is to define in
MCRC patients, the most appropriate tissue on which DNA
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Indeed, most studies published so far are based on the analysis of
genetic material extracted from primary tumours, whereas targeted
therapies are mainly directed at metastatic disease treatment. As
highlighted by several recent studies, this approach may have
limitations: (1) the primary tumour may not always be available;
(2) as indicated above, several genetic changes may occur between
the primary tumour and the corresponding metastases; and
(3) genetic analyses performed on paraffin-embedded tissues
may generate artefacts because of fragmentation and chemical
modification of DNA. Therefore, we think, as previously shown,
that genetic analysis based on highly sensitive detection from
blood of circulating mutant DNA might be of clinical interest
(Di Fiore et al, 2008a; Yen et al, 2009).
As the new markers will have to be validated by independent
studies, the challenge for the clinician, before treating patients, will
be the progressive integration of these markers in the routine and
the development of a decisional algorithm, which should probably
be stratified first by KRAS genotyping. In patients with KRAS
mutations, the choice of the most appropriate treatment is
problematic. Although the use of anti-EGFR mAbs is not
recommended in these patients, it should be underlined that
disease stability can be observed in up to 50% of chemorefractory
patients treated with anti-EGFR alone in association with CT
(Di Fiore et al, 2008b). In these patients, targeted therapies will
probably be based, in the future, on molecules able to inhibit
effectors of the EGFR transduction cascade and located down-
stream from the KRAS protein.
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